Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "an increase of inhaled oxygen concentration" assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment , and less patients 1/12 , 8.33 % " assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment , and less patients 1/12 , 8.33 % " assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment , and less patients 1/12 , 8.33 % " assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment , and less patients 1/12 , 8.33 % " assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment , and less patients 1/12 , 8.33 % " assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment and less patients 1 12 8 33 " assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment and less patients 1 12 8 33 " assertion.
- SUBJECT label "The improvement in hypoxia for the tocilizumab group" assertion.
- SUBJECT label "either Tocilizumab" assertion.
- SUBJECT label "to improve outcome" assertion.
- SUBJECT label "Thirty three patients" assertion.
- SUBJECT label "Thirty three patients" assertion.
- SUBJECT label "only one" assertion.
- SUBJECT label "only one" assertion.
- SUBJECT label "HBV reactivation" assertion.
- SUBJECT label "strict monitoring" assertion.
- SUBJECT label "BACKGROUND AND" assertion.
- SUBJECT label "the risk of hepatitis B virus reactivation in patients" assertion.
- SUBJECT label "HBsAg patients" assertion.
- SUBJECT label "Hyperbilirubinemia" assertion.
- SUBJECT label "the risk of reactivation" assertion.
- SUBJECT label "a total of 97 patients" assertion.
- SUBJECT label "the remaining 3 patients" assertion.
- SUBJECT label "the remaining 3 patients" assertion.
- SUBJECT label "the remaining 3 patients" assertion.
- SUBJECT label "by antiviral prophylaxis" assertion.
- SUBJECT label "Four patients 4 1 " assertion.
- SUBJECT label "The median disease follow up time" assertion.
- SUBJECT label "Of Seven patientsHBsAg 4" assertion.
- SUBJECT label "10 1007 s10620 020 06725 1 " assertion.
- SUBJECT label "rheumatoid" assertion.
- SUBJECT label "supplementary material" assertion.
- SUBJECT label "Seven patients" assertion.
- SUBJECT label "TCZ" assertion.
- SUBJECT label "aperfused boundary regionPBR of the sublingual arterial microvessels increased PBR" assertion.
- SUBJECT label "dglobal" assertion.